Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 12 , ISSUE S1 ( July, 2022 ) > List of Articles

Original Article

NAFLD vs MAFLD: South Asian NAFLD Patients don't Favor Name Change

Shivaram P Singh, Prajna Anirvan, Amna S Butt, Ananta Shrestha, Anuradha S Dassanayake, Bashir A Shaikh, Mamun A Mahtab

Keywords : NASH, Nomenclature, patients’ sentiments, South Asia, Steatohepatitis

Citation Information : Singh SP, Anirvan P, Butt AS, Shrestha A, Dassanayake AS, Shaikh BA, Mahtab MA. NAFLD vs MAFLD: South Asian NAFLD Patients don't Favor Name Change. Euroasian J Hepatogastroenterol 2022; 12 (S1):S1-S4.

DOI: 10.5005/jp-journals-10018-1363

License: CC BY-NC 4.0

Published Online: 10-08-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Abstract

Aim: There have been vociferous attempts to change the name of Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Associated Fatty Liver Disease (MAFLD). Of the many arguments put forth in support of this, an important one is the presumed demand by patient groups insisting on the change. However, this claim does not have credible evidence to support it. Therefore, we decided to conduct a survey among South Asian NAFLD patients to understand their perspectives with regard to the change in nomenclature. Materials and methods: The study was conducted at multiple centers across South Asia from January 2021 to June 2021. Patients were surveyed using an 8-question survey questionnaire and responses were categorized by multiple-choice format. Results: Of 218 patients surveyed, 80.3% of the patients were not aware of the entity “NAFLD” before they were first diagnosed. Although 74.3% of patients admitted to being questioned about alcohol intake at the time of the first diagnosis, 75.9% of female patients were not questioned regarding this. After being labelled NAFLD, 92.1% of patients were never questioned again about alcohol intake. While 86.3% of patients found the term “NAFLD” consoling, 83% did not feel that “Non” in NAFLD trivialized their problem. In addition, only 6.9% of patients were scared of developing cardiovascular disease. Conclusion: The term “NAFLD” destigmatizes patients of the taboo associated with alcohol use. It was found to be consoling to most patients and they did not feel it trivialized their problem. A change of name without considering patients’ perspectives and peculiarities specific to different populations will have enormous ramifications for both patients and physicians. Clinical significance: Our survey clearly shows that patients are happy with the term “NAFLD” and it effectively destigmatizes them from the taboo of alcohol. This would lead to higher compliance with management and greater patient participation in future studies and trials.


PDF Share
  1. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73(1):202–209. DOI: 10.1016/j.jhep.2020.03.039.
  2. Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158(7):1999–2014.e1. DOI: 10.1053/j.gastro.2019.11.312.
  3. Eslam M, Ratziu V, George J. Yet more evidence that MAFLD is more than a name change. J Hepatol 2021;74(4):977–979. DOI: 10.1016/j.jhep.2020.12.025.
  4. Shiha G, Korenjak M, Eskridge W, et al. Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol 2021;6(1):73–79. DOI: 10.1016/S2468-1253(20)30294-6.
  5. Samji NS, Snell PD, Singal AK, et al. Racial disparities in diagnosis and prognosis of nonalcoholic fatty liver disease. Clin Liver Dis 2020;16(2):66–72. DOI: 10.1002/cld.948.
  6. Sherif ZA, Saeed A, Ghavimi S, et al. Global epidemiology of non-alcoholic fatty liver disease and perspectives on US minority populations. Dig Dis Sci 2016;61(5):1214–1225. DOI: 10.1007/s10620-016-4143-0.
  7. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73–84. DOI: 10.1002/hep.28431.
  8. Nápoles-Springer AM, Santoyo J, Houston K, et al. Patients’ perceptions of cultural factors affecting the quality of their medical encounters. Health Expect Int J Public Particip Health Care Health Policy 2005;8(1):4–17. DOI: 10.1111/j.1369-7625.2004.00298.x.
  9. Molzahn AE, Northcott HC. The social bases of discrepancies in health/illness perceptions. J Adv Nurs 1989;14(2):132–140. DOI: 10.1111/j.1365-2648.1989.tb00911.x.
  10. Yu BC-Y, Kwok D, Wong VW-S. Magnitude of nonalcoholic fatty liver disease: Eastern perspective. J Clin Exp Hepatol 2019;9(4):491–496. DOI: 10.1016/j.jceh.2019.01.007.
  11. K Pati G, P Singh S. Nonalcoholic fatty liver disease in South Asia. Euroasian J Hepato-Gastroenterol 2016;6(2):154–162. DOI: 10.5005/jp-journals-10018-1189.
  12. Ahmed SM, Lemkau JP. Cultural Issues in the primary care of South Asians. J Immigr Health 2000;2(2):89–96. DOI: 10.1023/A:1009585918590.
  13. Lucas A, Murray E, Kinra S. Heath beliefs of UK South Asians related to lifestyle diseases: a review of qualitative literature. J Obes 2013;2013:827674. DOI: 10.1155/2013/827674.
  14. Goh GBB, Kwan C, Lim SY, et al. Perceptions of non-alcoholic fatty liver disease–an Asian community-based study. Gastroenterol Rep 2016;4(2):131–135. DOI: 10.1093/gastro/gov047.
  15. Malik K, Benegal V, Murthy P, et al. Clinical audit of women with substance use disorders: findings and implications. Indian J Psychol Med 2015;37(2):195–200. DOI: 10.4103/0253-7176.155620.
  16. Prabhu S, Patterson DA, Dulmus CN, et al. Prevalence, nature, context and impact of alcohol use in India: recommendations for practice and research. Brown Sch Fac Publ; 2010. Available from: https://openscholarship.wustl.edu/brown_facpubs/25.
  17. Benegal V. India: alcohol and public health. Addiction 2005;100(8): 1051–1056. DOI: 10.1111/j.1360-0443.2005.01176.x.
  18. Alem SA, Gaber Y, Abdalla M, et al. Capturing patient experience: a qualitative study of change from NAFLD to MAFLD real-time feedback. J Hepatol 2021;74(5):1261–1262. DOI: 10.1016/j.jhep.2021.01.022.
  19. Chute CG. Clinical classification and terminology. J Am Med Inform Assoc JAMIA 2000;7(3):298–303. DOI: 10.1136/jamia.2000.0070298.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.